Vaxart, Inc. (VXRT) dividend history

VXRTOTCBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 10/30

$0.48+0.02 (+5.04%)

Close on Oct 19, 2026Market cap $115.61MP/E 4.0Yield –

Dividend payments

Every dividend Vaxart has paid, newest first. Shares held at the close of the last day with dividend receive it; shares bought on the ex-dividend date or later do not.

Ex-dividend	Last day to buy	Record	Payable	Declared	Per share	Source
Nov 9, 2012	Nov 8, 2012	Oct 26, 2012	Nov 8, 2012	Oct 16, 2012	Irregular$12.188	10-Q

Per share as declared at the time. Source document: the dividend announcement filed with the SEC (press release or 8-K) where one exists, otherwise the quarterly or annual report covering the declaration.

Where these numbers come from

Parsed from the XBRL in Vaxart's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-11 reverse split on Feb 14, 2018
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is VXRT.

Compare: VXRT vs VIR · VXRT vs VALN · VXRT vs NVAX · VXRT vs ALEC · VXRT vs FDMT

Revenue growth22.3% · median 151.2%

Operating margin16.6% · median -69.8%

Net margin16.0% · median -39.8%

Company	Revenue	Growth
NVAX	$411.65M	-61.3%
VIR	$302.80M	+1696.0%
VXRT	$181.27M	+22.3%
ALEC	$173.47M	+151.2%
VALN	€142.94M	-27.2%
FDMT	$96.06M	+79952.5%

Company

Next earnings (est.): Mar 11, 2027, during market hours
Exchange: OTC
Industry: Biological Products, (No Diagnostic Substances)
Fiscal year ends: December 31
Employees: 65
Held by institutions: 0.0%
Auditor: WithumSmith+Brown, PC
SEC CIK: 72444

Advertisement
300 × 250

See a number that looks wrong?